SEARCH

SEARCH BY CITATION

References

  • 1
    United States Renal Data System. USRDS 2003 Annual Data Report: Atas of End-Stage Renal Disease in the United States. Bethesda , MD : National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases, 2003.
  • 2
    Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605612.DOI: 10.1056/NEJM200003023420901
  • 3
    Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 12891295.DOI: 10.1111/j.1600-6143.2004.00515.x
  • 4
    Gourishankar S, Hunsicker LG, Jhangri GS, Cockfield SM, Halloran PF. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14: 23872394.DOI: 10.1097/01.ASN.0000085019.95339.F0
  • 5
    Levey AS, Coresh J, Balk E et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137147.
  • 6
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 7
    Kasiske BL, Andany MA, Hernandez D et al. Comparing methods for monitoring serum creatinine to predict late renal allograft failure. Am J Kidney Dis 2001; 38: 10651073.
  • 8
    Kasiske BL, Heim-Duthoy KL, Tortorice KL, Rao KV. The variable nature of chronic declines in renal allograft function. Transplantation 1991; 51: 330334.
  • 9
    Moss A, Najarian JS, Sutherland DE et al. 5000 kidney transplants–a single-center experience. In: CeckaJM, TerasakiPI, eds. Clinical Transplants. Los Angeles : UCLA Immunogenetics Center , 2000; 159171.
  • 10
    Anjum S, Andany MA, McClean JC, Danielson B, Kasiske BL. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am J Transplant 2002; 2: 179185.DOI: 10.1034/j.1600-6143.2002.020210.x
  • 11
    Rush D, Nickerson P, Gough J et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol 1998; 9: 21292134.
  • 12
    Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155163.
  • 13
    Wright JT, Jr., Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 24212431.DOI: 10.1001/jama.288.19.2421
  • 14
    The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 18571863.DOI: 10.1016/S0140-6736(96)11445-8
  • 15
    Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877884.DOI: 10.1056/NEJM199403313301301
  • 16
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 14561462.DOI: 10.1056/NEJM199311113292004